TRAF6 and IRF7 Control HIV Replication in Macrophages by Sirois, Mélissa et al.
TRAF6 and IRF7 Control HIV Replication in Macrophages
Me ´lissa Sirois
1, Lynda Robitaille
1, Robin Allary
1, Mohak Shah
2, Christopher H. Woelk
3,J e ´ro ˆme
Estaquier
1,4, Jacques Corbeil
1*
1Department of Molecular Medicine, Infectious Disease Research Center, CHUL Research Center and Laval University, Que ´bec, Que ´bec, Canada, 2Department of Electrical
and Computer Engineering, Centre for Intelligent Machines, McGill University, Montreal, Que ´bec, Canada, 3Department of Medicine, University of California San Diego,
San Diego, California, United States of America, 4CNRS FRE3235, Universite ´ Rene ´ Descartes Paris, Paris, France
Abstract
The innate immune system recognizes virus infection and evokes antiviral responses which include producing type I
interferons (IFNs). The induction of IFN provides a crucial mechanism of antiviral defense by upregulating interferon-
stimulated genes (ISGs) that restrict viral replication. ISGs inhibit the replication of many viruses by acting at different steps of
their viral cycle. Specifically, IFN treatment prior to in vitro human immunodeficiency virus (HIV) infection stops or significantly
delays HIV-1 production indicating that potent inhibitory factors are generated. We report that HIV-1 infection of primary
human macrophages decreases tumor necrosis factor receptor-associated factor 6 (TRAF6) and virus-induced signaling
adaptor (VISA) expression, which are both components of the IFN signaling pathway controlling viral replication. Knocking
down theexpressionofTRAF6 inmacrophagesincreasedHIV-1replicationand augmented the expression ofIRF7butnotIRF3.
Suppressing VISA had no impact on viral replication. Overexpression of IRF7 resulted in enhanced viral replication while
knocking down IRF7 expression in macrophages significantly reduced viral output. These findings are the first demonstration
that TRAF6 can regulate HIV-1 production and furthermore that expression of IRF7 promotes HIV-1 replication.
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Introduction
Infection by RNA viruses, such as HIV-1, initiates antiviral
innate immune responses by inducing type I IFNs [1,2]. The
treatment of primary human macrophages in vitro with type I IFN
prior to HIV-1 infection inhibits virus replication, indicating that
potent inhibitory factors are present [3,4]. However, pre-treatment
is not a viable clinical option and, ultimately, innate immune
responses in vivo fail to completely protect the human host even
though genes integral to host defense are expressed. This may be
due to the deregulation by HIV-1 of the signaling events necessary
for induction of an appropriate innate immune response mediated
by IFN or that HIV-1 replication outpaces these defenses. Type I
IFNs display diverse biological effects that restrict virus replication
by upregulating the expression of numerous genes (ISGs) [5–13].
For example, eukaryotic translation initiation factor 2-alpha kinase
(EIF2AK2, also known as PKR), oligoadenylate synthetase 1 (OAS1)
and interferon-stimulated gene 15 (ISG15) are known to be anti-HIV
ISGs [14–16]. However, HIV-1 circumvents the protective effects
of IFN and may even upregulate certain ISGs to its benefit [17].
Recently, Smith and collaborators identified ISGs expressed in
inguinal lymph nodes that were positively associated with HIV-1
viral replication [18]. Moreover, it has been shown that the level of
Type I IFN correlates with AIDS pathogenesis [19].
Production of IFN is induced by two major receptor systems for
detecting RNA viruses: the toll-like receptors (TLRs) and
cytoplasmic retinoic acid-inducible gene I (RIG-I)-like helicases
(RLHs) [20,21]. The adaptor molecule TRAF6 has been shown to
be involved in the TLR signaling pathway and activates IRF7,
IRF3 and nuclear factor kappa B (NFkB) [22,23]. Furthermore,
the RLH signaling pathway involves RNA helicase RIG-I and
melanoma differentiation associated protein-5 (MDA5) [24,25]
that interact with VISA through a caspase recruitment domain
(CARD/CARD) interaction [26–29]. VISA induces I-kappaB
kinase (IKKe and TANK binding kinase 1 (TBK1) which are
responsible for the activation of IFN-regulatory factors (IRF3 and
IRF7) through phosphorylation and consequently the production
of type 1 IFN [30,31]. IFN production is cell type and stimuli
specific and our aim was to ascertain the phenotype in the process
of HIV-1 infection of primary human macrophages.
The goal of this study was to identify factors belonging to the
interferon pathway that are altered during HIV-1 infection which
contribute to the modulation of viral replication. We identified
genes involved in the IFN signaling pathway that were impacted
by HIV-1 infection of human primary macrophages. Our model is
highly relevant to HIV-1 infection since macrophages are among
the first cell types infected during transmission of HIV-1. In
addition, macrophages infection by SIV is similar to that of CD4+
T cells in the acute phase of SIV infection [32]. We demonstrated
that IFNa2 pre-treated macrophages, infected or not with HIV-1,
modulated genes that were involved in the transcriptional
regulation of the IFN pathway. Among them, HIV-1 downreg-
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e28125ulated TRAF6 and VISA gene expression. The downregulation of
TRAF6 in macrophages infected with HIV-1 resulted in enhanced
viral replication. Suppression of TRAF6 resulted in increased
expression of IRF7. Overexpression of IRF7 lead to enhanced
viral expression and suppression of IRF7 resulted in diminished
viral output. The characterization of antiviral innate immunity
genes modulated by HIV-1 infection provides a greater under-
standing of the mechanisms that may be used to combat the virus
and improve antiviral treatments.
Results
Type I IFNa2 inhibits HIV-1 replication in primary
macrophages
Kornbluth and collaborators demonstrated that macrophages
treated 18 hours with 1000 IU/ml of IFNa2 prior to HIV-1 NL4-
3BaLenv strain infection inhibited viral production [3]. To
ascertain the stage at which HIV-1 replication was curtailed in
the IFNa2 pre-treated macrophages, we monitored viral replica-
tion by quantifying TAT spliced message expression by qRT-PCR,
a marker of productive viral transcription distinct from incoming
viral genomic RNA. Treatment of infected cells with a non-
nucleoside reverse transcriptase inhibitor, efavirenz, blocked all
steps of infection after entry and prevented the appearance of TAT
spliced message, demonstrating specificity for new viral production
(data not shown). TAT spliced message could be detected as early as
2 hours post-infection, remained stable until 8 hours, and
increased over time thereafter in macrophages infected with
HIV-1. It is possible that initial TAT spliced detection could be due
to viral nucleic content that’s encapsidated within virions. Still,
kinetic was greatly delayed in IFNa2 pre-treated macrophages
infected with HIV-1, where initial detection was observed at
120 hours and subsequently increased over time (Fig. 1). Similarly,
HIV-1 p24 antigen could be detected in cellular supernatant in
untreated samples at day 7 after infection. For the purpose of this
study, we used the early TAT spliced message detection since the
HIV-1 p24 can only be detected from day 7 in our model.
To determine the effect of HIV-1 on the IFN response and
uncover potential effectors of HIV-1 replication, gene expression
analysis in HIV-infected and non-infected IFNa2-treated macro-
phages was compared. This strategy enabled the identification of
interferon-induced genes that were differentially modulated during
HIV-1 infection.
HIV-1 modulates TRAF6 and VISA gene expression in
IFNa2 pre-treated macrophages
To identify specific genes involved in Type I IFN signaling
modulated by HIV-1 infection, gene expression in IFNa2 pre-
treated macrophages infected or not with HIV-1 was measured at
2, 4, 8, and 24 hours post-infection using high-density oligonu-
cleotide microarrays (U133 Plus 2.0 arrays). Identification of the
most highly modulated genes was ascertained by applying the
short time series analysis framework of Shah and Corbeil with a
linear kernel [33]. The application of linear kernel in conjunction
with the framework results in a configuration that effectively scores
the genes based on averaged differences between consecutive
measurements scaled by their respective means, and this, over all
the time points in the two conditions tested. We then compared
the results obtained to untreated and uninfected control cultures.
The most significantly up or downregulated genes were then
identified as the ones obtaining extreme (respectively high and low)
scores. This analysis demonstrated significant differences in IFNa2
pre-treated macrophages infected with HIV-1 when compared to
the IFNa2 pre-treated macrophages only. Analysis of the top 500
differentially expressed genes (maximum scores of comparison)
between IFNa2 treated macrophages that were either infected or
not with HIV-1 through all time points was performed using
Figure 1. Type I IFNa2 inhibits HIV-1 replication in primary
macrophages. A) Gene expression of TAT spliced at 2, 4, 8, 24, 120 and
168 hours post-infection of macrophages. The macrophages were
incubated in the absence or presence of IFNa2 (1000 UI/ml for
18 hours). The expression level was calculated by qRT-PCR assessments
of triplicates and normalized to the level of 18 S. Results shown are a
representative of 2 independent experiments. A.U. corresponds to
arbitrary units. B) Cell-free culture supernatants were collected at 24, 72,
120 and 168 hours post-infection and analyzed for p24 content. Results
shown represent 2 combined independent experiments.
doi:10.1371/journal.pone.0028125.g001
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(DAVID) [34]. This analysis identified 32 significant functions.
Table 1 displays the ten most significant functional categories
associated with genes differentially modulated. The same gene can
be related to more than one function and the statistical significance
takes account of this fact. Examination indicated that most of these
functions are related to transcription. Table 2 provides a short list
of known genes associated with IFN response. The expression of
most known genes related to the interferon response, such as OAS1
and 2 (29,5 9 oligoadenylate synthetase 1 and 2), MX1 and 2
(myxovirus (influenza virus) resistance 1 and 2) and IRF7 in IFNa2
pre-treated macrophages compared to untreated control were
detected early and throughout the time course. Furthermore,
HIV-1 antiviral factors, such as APOBEC3G, APOBEC3A and
TRIM22, were upregulated in IFNa2 pre-treated macrophages
compared to untreated control. However, most of these IFN-
related genes were unaffected by the presence of HIV-1 after the
IFNa2 treatment.
Our intent was to identify genes related to interferon that were
inhibited by HIV-1. Table 3 shows candidate interferon-related
genes from the top 500 genes that were modulated significantly
when HIV-1 was present. These genes represent potential
regulators of interferon and innate immunity pathways that are
modulated by HIV-1 infection in macrophages. We were
specifically interested in VISA and TRAF6 since these two factors
represent key control points in the regulation of the IRFs pathway,
ISGs production and innate immunity, and expression of these
two genes was reduced when HIV-1 was present. Therefore, we
examined TRAF6 and VISA gene expression over time to assess the
dynamics of their expression. As shown by the oligonucleotide
array analysis, the greatest differences in gene expression for these
two genes occurred at 8 hours post-infection (Fig. 2A). To validate
the modulation of HIV-1 on host gene expression of the IFNa2
pre-treated macrophages, we evaluated independent donors,
under the same conditions as the oligonucleotide array experi-
ment. Altogether we used 15 independent donors to perform the
experiments described (see material and methods section). We
tested the expression of TRAF6 and VISA, using qRT-PCR (Fig.
2B). TRAF6 and VISA gene expression were upregulated in IFNa2
pre-treated macrophages but downregulated after HIV-1 infection
at 8 hours. The downregulation of TRAF6 and VISA after HIV-1
infection of IFNa2 pre-treated macrophages suggested a possible
role for these factors in the regulation of HIV-1 expression.
TRAF6 but not VISA controls the level of expression of
IRF7 and HIV-1 replication
To analyze the impact of TRAF6 and VISA in the context of
HIV-1 infection, we suppressed both genes independently using
siRNA. Gene expression inhibition levels of 65% and 61% were
obtained for TRAF6 and VISA respectively as compared to a non-
targeted siRNA negative control (Fig. 3A). To further decipher the
role of TRAF6 in the IFN antiviral response, we evaluated HIV-1
replication, 24 hours after infection of IFNa2 pre-treated or not
macrophages. HIV-1 replication was significantly upregulated in
macrophages with knockdown expression of TRAF6 as compared
to the control pre-treated macrophages independently of IFN
treatment (Fig. 3B). This is the first report that TRAF6 can
function to limit HIV-1 replication. No significant differences were
detected in macrophages treated with VISA siRNA when
compared to the negative control siRNA irrespective of the
presence of IFN pretreatment (Fig. 3B).
In this transduction pathway, TRAF6 activates IRF3 and IRF7
to promote their transcriptional functions [22,23,30,31]. There-
fore, we evaluated the expression of IRF3 and IRF7 genes in this
context. As shown in figure 3C and D, upregulation of HIV-1
replication in macrophages with knockdown of TRAF6 expression
seen in figure 3B is accompanied by significant overexpression of
IRF7 compared to the HIV-1 infected negative control (Fig 3C).
No significant difference in the expression of IRF7 in HIV-1
infected macrophages with knockdown of VISA expression was
Table 1. Ten most significant functional categories
associated with genes differentially modulated in IFNa2 pre-
treated macrophages infected or not with HIV-1.
Function p-value No. of genes
Phosphoprotein 1,9E-08 126
Alternative splicing 9,1E-05 127
Nucleus 3,3E-04 90
RNA-binding 1,3E-03 19
DNA-binding 2,2E-03 47
Chromosomal rearrangement 3,0E-03 12
Transcription 5,4E-03 46
Transcription regulation 6,6E-03 45
Peroxidase 6,9E-03 4
Cytoskeleton 7,7E-03 14
Functional categories were obtained using the DAVID Bioinformatics tool.
Selection of the ten most significant functional categories out of 32 functions
involved the top 500 genes differentially modulated in IFNa2 pre-treated
macrophages infected or not with HIV-1.
doi:10.1371/journal.pone.0028125.t001
Table 2. Peak expression and time point of known genes
associated in IFN response that were modulated in IFNa2
pre-treated macrophages compared to untreated control.
IFN-related
genes
Reference
Sequence
Peak expression
(Fold induction)
Time
(hours)
APOBEC3A NM_145699 1267 2
APOBEC3G NM_021822 3 2
EIF2AK2 NM_002759 3 4
G1P2 (ISG15) NM_005101 47 2
G1P3 NM_002038 10 24
IFI27 NM_005532 1131 4
IFI44L NM_006820 1182 2
IFIT2 NM_001547 74 2
IFIT3 NM_001549 32 8
IFITM1 NM_003641 707 4
IFITM3 NM_021034 27 8
IRF1 NM_002198 3 8
IRF7 NM_001572 12 2
ISG29 NM_002201 702 2
MX1 NM_002462 197 8
MX2 NM_002463 24 2
OAS1 NM_016816 33 2
OAS2 NM_016817 41 2
OASL NM_003733 446 2
TRIM22 NM_006074 11 2
doi:10.1371/journal.pone.0028125.t002
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TRAF6 knockdown macrophage, while no significant difference in
the expression of IRF3 in the VISA siRNA treated targets was
found (Fig. 3D). This suggested that VISA was not responsible for
the observed increase in viral replication. It is possible that
alternative effectors can substitute for its function or that its
modulation has no bearing on HIV-1 production.
To validate our finding at the protein expression level, we
performed western blotting for both IRF3 and IRF7. Levels of
these proteins in lysates of TRAF6 knockdown or control siRNA
treated (200 nM) macrophages from three independent donors
were normalized using b-actin. As seen in figure 3E, IRF3 is
downregulated (0.83 fold, corresponding to a 17% reduction) and
IRF7 is upregulated (3.59 fold) in TRAF6 knockdown macro-
phages compared to control siRNA. The protein data confirmed
our gene expression results and suggested that the regulation of
HIV-1 replication by TRAF6 involved IRF7.
IRF7 downregulation decreases HIV-1 replication
To elucidate if IRF7 directly alters HIV-1 replication, we first
evaluated the effect of downregulation of IRF7 expression using
siRNA. Macrophages were transfected with specific siRNAs
targeted against IRF7 or silencer negative control. As shown in
figure 4, transfection of specific IRF7 siRNA (50 nM) significantly
reduced IRF7 mRNA (55% reduction) (Fig. 4A) and protein (42%
reduction) (Fig. 4B) expression. The inhibition of IRF7 resulted in
a comparable downregulation of HIV-1 replication (51%
reduction) (Fig. 4C).
IRF7 overexpression increases HIV-1 replication
To confirm that IRF7 promoted HIV-1 replication, IRF7 was
overexpressed in macrophages followed by infection with HIV-1 at
a multiplicity of infection (MOI) of 0.002. While protein levels
expression were only increased modestly (2 fold) by transfection of
an IRF7 expressing vector (Fig. 5A) HIV-1 replication was
markedly upregulated (14 fold) indicating enhanced viral replica-
tion when IRF7 is present in sufficient quantity (Fig. 5B). This
occurred despite IFNa/b expression in the presence or absence of
IRF7 overexpression (data not shown). This is the first demon-
stration that links IRF7 to an increased HIV-1 replication.
Discussion
Our investigation demonstrated the capability of HIV-1
infection to alter critical early events involved in appropriate
induction of the IFN response. This ability emphasizes the
importance of the IFN signaling pathways in controlling HIV-1
replication and suggests that HIV-1 has evolved mechanisms to
compromise this innate host immune response to favor its
propagation. We present evidence that TRAF6, important for
transcriptional regulation of the interferon pathway, is affected
early in the process of HIV-1 infection of primary human
Table 3. Peak expression and time point of candidate genes associated with IFN response that were modulated in IFNa2 pre-
treated macrophages compared to untreated control and modulated by HIV-1.
IFN-related
genes
Reference
Sequence
Peak expression
IFNa2/CTRL
(Fold induction)
Time
(hours)
Peak expression
IFNa2/HIV infection
(Fold induction)
Time
(hours)
BIRC3 NM_001165 7 2 3,5 2
CCL5 NM_002985 8 2 4 8
CD38 NM_001775 39 4 13 16
CEBPD NM_005195 2 8 1 16
CHI3L1 NM_001276 2 2 1 2
CXCL10 NM_001565 124 2 31 2
CXCL11 NM_005409 118 2 39 8
CXCL9 NM_002416 28 2 9 16
EHF NM_012153 4 8 1 16
HMGA1 NM_145899 2 8 1 24
LILRB2 NM_005874 16 8 8 2
NCOA3 NM_181659 2 2 4 4
OGT NM_181632 5 8 4 2
PIGR NM_002644 3 8 1,5 8
PIP5K2A NM_005028 3 8 1,5 8
SAMHD1 NM_015474 2 8 1 8
TAP2 NM_000544 16 2 8 2
TCF4 NM_003199 2 2 0,7 16
TRAF6 NM_004620 2 8 1 8
TXNIP NM_006472 2 8 1 16
VISA NM_020746 2 8 1 8
Selection of the top 500 most modulated genes when comparing the IFNa2 pre-treated macrophages infected or not with HIV-1. Of these, 55 were related to interferon
as a keyword. From these 55, 21 were upregulated by interferon as compared to untreated control (peak expression and time point) but modulated differentially when
HIV-1 was added. Those genes may represent interferon effectors that are modulated by HIV-1 infection during the interferon response.
doi:10.1371/journal.pone.0028125.t003
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in a significant augmentation in HIV-1 replication, as assessed by
the expression of TAT spliced message.
TRAF6 has been shown to be important for control of
replication of other viruses. Konno and collaborators reported
that the absence of TRAF6 in TRAF6
-/- mouse embryonic
fibroblasts, (MEF cells) resulted in enhanced replication of RNA
viruses such as Newcastle disease virus and encephalomyocarditis
virus [23]. Similarly, TRAF6 has been shown to be critical for
IFNa and b induction in response to vesicular stomatitis virus
infection and intracellular double-stranded RNA, poly (I:C) [35].
All of these studies confirm that TRAF6 is induced as part of the
normal innate immune response against viruses and our findings
indicate it plays a similar role in curtailing HIV-1 replication.
Interestingly, our results also suggest that HIV-1 has devised
strategies to circumvent this inhibition. HIV-1 infection reduced
TRAF6 gene expression with the resulting enhanced viral
replication. Despite being upregulated by interferon and repressed
by HIV-1 infection, VISA, another important mediator of innate
immunity, did not have any impact on HIV-1 replication in our
study. Instead, HIV-1 replication was similar to that of the control.
There may be compensatory mechanisms circumventing the
ablation or reduction of VISA expression during HIV-1 infection.
TRAF6 is implicated in the activation of the transcription
factors IRF3 and IRF7 [22,36]. TRAF6 polyubiquitinates IRF7, a
post-translational modification necessary for the IFN production
as demonstrated in fibroblasts [22,36]. Both transcription factors
are key regulators of IFN production [37–44] and have essential
roles in the activation of antiviral immunity [44–46]. Certain
viruses have evolved mechanisms to overcome their effect such as
the Thogoto virus ML protein that reportedly inhibits the
activation of IRF7 [47]. In addition, vesicular stomatitis virus
was more efficient at infecting fibroblasts when IRF7 was ablated
[48]. In contrast, IRF7 increased human papillomavirus (HPV)
type 8 late promoter activity via direct binding to viral DNA and
IRF3 induced strong HPV8 suppression in primary keratinocytes.
This is consistent with our study where IRF7 promoted HIV-1
replication [49]. The knockdown of TRAF6 induced the
expression of IRF7 but decreased the expression of IRF3 at both
the gene and protein levels.
Overexpression of IRF7 resulted in a significant increase in
HIV-1 replication in primary human macrophages. Moreover,
inhibition of IRF7 brought about a concomitant decrease of viral
output. Our results show that when TRAF6 is reduced, IRF7 is
overproduced and contributes to enhanced viral replication.
Recently, a study by Smith and collaborators identified host genes
expressed in inguinal lymph nodes that were associated determi-
nants of HIV-1 viral load [18]. Moreover, in primate models,
higher levels of type 1 interferon characterize the pathogenic state
[19]. Consistent with our results with IRF7, these analyses reflect
an antiviral host response mediated by the interferon pathway that
is associated with higher viral load rather than inhibition of HIV-1
Figure 2. HIV-1 modulates TRAF6 and VISA expression in IFNa2 pre-treated macrophages. A) Intensity of the expression of the genes of
interest obtained from the oligonucleotide array analysis (U133 Plus 2.0 array) at 2, 4, 8 and 24 hours post-infection of macrophages. Cells were
treated with IFNa2 (1000 UI/ml for 18 hours) with or without HIV-1. B) Validation of the regulation of gene modulation by HIV-1 in IFNa2 pre-treated
macrophages (differentiated with human serum) at 8 hours post-infection. Non-IFNa2 treated and non-HIV infected macrophages were used as
negative control. An * denotes a significant difference (P,01, paired t-test) between IFNa2 pre-treated or not macrophages. The expression level was
calculated by qRT-PCR assessments obtained from four donors and normalized to the level of 18S.
doi:10.1371/journal.pone.0028125.g002
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response to its own benefits. IRF7 could contribute to enhanced
HIV-1 replication by several potential, non-exclusive mechanisms.
IRF7 could facilitate Long Terminal Repeat (LTR) driven
expression of the virus and/or favor transcriptional activation of
cellular genes that could contribute to increased viral output.
However, on its own IRF7 is not capable of enhancing the activity
of a LTR-luciferase reporter in primary human macrophages
(Figure S1). Thus, if IRF7 modulates the HIV-1 LTR, it may
require interaction with another protein. In opposition, IRF1, a
positive control in this setting, could readily enhance LTR-driven
replication. Presumably, IRF7 could facilitate the translocation
Figure 3. TRAF6 but not VISA controls the level of expression of IRF7 and HIV replication. Primary human macrophages were subjected to
siRNA knockdown for TRAF6 and VISA. The concentration of siRNA used was 200 nM. A) Percentages of inhibition of TRAF6 and VISA in the presence
of specific siRNA targeting both gene individually [n=3] compared to a control non-targeted siRNA [n=3]. Level of expression was measured by qRT-
PCR B) Macrophages were all infected with HIV-1 with and without an IFNa2 pretreatment, and treated with specific siRNA. The level of TAT spliced
message measured 24 hours post-infection in TRAF6 and VISA conditions were compared to the negative control siRNA. C) Level of IRF7 and D) Level
of IRF3 message expression in the absence of IFNa2 when TRAF6 and VISA are repressed by siRNA compared to the negative control siRNA. The qRT-
PCR results were normalized to the level of 18S. An * denotes a significant difference (P,0.05, one sample t-test) compared to the negative control
siRNA. Each symbol in a group represents one independent donor. E) Western blot for IRF3 and IRF7, 24 hours post-infection in macrophages with
TRAF6 suppression compared to siRNA control. The densitometry of the bands was normalized to that of b-actin and shows a decrease in protein
level of IRF3 and an increase of IRF7. The ratio is shown next to the respective panels. Results shown are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0028125.g003
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replication since NFkB is a potent activator of LTR-driven
expression of the virus. Although demonstrated in Jurkat T cells,
IRF7 could, in a situation analogous to IRF1, interact with
NFkB to promote this LTR-driven transcription [50,51].
Preliminary chromatin immunoprecipitation experiments (ChIP
on chip monitoring 19,000 genes) using HIV-infected primary
macrophages indicate enrichment for the promoter regions of
three genes that stimulate the NFkB pathway, coactivator-
associated arginine methyl transferase 1 (CARM1), B-cell CLL/
lymphoma 10 (BCL10) and solute carrier family 20 member
(SLC20A1) [52–54]. These interesting candidates warrant
Figure 4. IRF7 expression modulates HIV-1 replication in primary macrophages. A) Level of IRF7 gene expression in macrophages treated
with siRNA targeting IRF7 (50 nM) [n=3] compared to a control non-targeted siRNA [n=3] resulted in a 55% reduction in IRF7 gene expression. The
qRT-PCR results were normalized to the level of 18 S. B) Western blot for IRF7 protein treated as in panel A shows a decrease of 42% for IRF7 protein.
The densitometry of the bands was normalized to that of b-actin. Results shown are representative of 2 independent experiments. C) Level of TAT
spliced expression following inhibition (51%) by IRF7 as compared to control. The qRT-PCR results were normalized to the level of 18 S. An * denotes a
significant difference (P,0.001, one sample t-test) compared to the negative control siRNA. Each symbol in a group represents one independent
donor.
doi:10.1371/journal.pone.0028125.g004
Figure 5. IRF7 overexpression increases HIV-1 replication in primary macrophages. A) Western blot for IRF7 protein, 24 hours post-
transfection of macrophages overexpressing IRF7 showed a 2 fold increase compared to empty vector control. The densitometry of the bands was
normalized to that of b-actin. The ratio is shown next to the respective panels. Results shown are representative of 2 independent experiments. B) TAT
spliced expression was augmented 14 fold in primary human macrophages overexpressing IRF7 compared to empty vector control. The qRT-PCR
results were normalized to the level of 18 S. An * denotes a significant difference (P,0.05, one sample t-test) compared to the empty vector control.
Each symbol in a group represents one independent donor.
doi:10.1371/journal.pone.0028125.g005
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replication.
Alternatively, the increase in IRF7 expression together with the
reduction in IRF3 expression might favour the formation of IRF7
homodimers instead of IRF3 homodimers or IRF3/IRF7
heterodimers. IRF3 and IRF7 require dimerization among other
post-translational modifications to act as transcription factors. This
shift in the transcription factor complex composition would induce
the activation of a distinct set of genes some of which could
contribute to HIV-1 replication. There is evidence in paramyxo-
virus infection of lymphocyte B-cells that the relative ratio of
IRF3/IRF7 contributed to differential expression of IFNa2-
related genes [55].
In conclusion, we demonstrated that TRAF6 is an important
factor involved in the replication of HIV-1 in primary human
macrophages. HIV-1 infection downregulated TRAF6 expression.
In the absence of TRAF6, IRF7 is overproduced and contributes
to enhanced HIV-1 replication. It is important to elucidate how
HIV-1 interferes with this innate immunity in order to favour its
own replication.
Methods
Cells
Monocytes were recovered from whole blood of healthy human
donors by negative selection with RosetteSep
TM human monocyte
enrichment cocktail (Stem Cell Technologies Inc, Vancouver, BC),
according to the manufacturer’s instructions. A total of 15
independent donors were utilized for the experiments described in
this manuscript. Monocytes to be differentiated into macrophages
were plated into T25 flasks in RPMI 1640 supplemented with 10%
human serum (Wisent Inc., Que ´bec, QC) for oligonucleotide array
experiments and subsequent validation by real-time quantitative
RT-PCR (qRT-PCR). qRT-PCR quantification, knockdown
assays and western blot assays used monocytes plated in RPM1
1640 with 10% fetal bovine serum (Invitrogen Canada, Burlington,
ON) and 25 ng/ml of monocyte/macrophage colony-stimulating
factor (M-CSF) (Genscript Corp, Piscataway, NJ) for differentiation
into macrophages. Cell-surface expression of CD14 was character-
ized by using fluorescein isothiocyanate (FITC)-conjugated mAb
(cloneMEM-18)(Cedarlane LaboratoriesLimited,Burlington,ON)
afterallowingmonocytestodifferentiatefor5 days. Bythiscriterion,
the cells were .97% monocytes differentiated macrophages
(MDMs) as assessed by flow-cytometry evaluation by using EPICS
XL (Beckman Coulter, Fullerton, CA) (data not shown).
Production of virus stocks
Virus stocks were produced by the transfection of 293T cells
using the calcium phosphate co-precipitation method [56]. The
infectious molecular clone used in this study was pNL4-3BaLenv.
The pNL4-3BaLenv vector was generated by replacing the env gene
of the T-tropic HIV-1 strain, NL4-3, with that of the macrophage-
tropic HIV-1 BaL strain, thus resulting in an infectious molecular
clone with macrophages-tropic properties [57] (pNL4-3BaLenv was
kindly provided by M. J. Tremblay, Laval University, Que ´bec,
QC). Supernatants from transfected cells were clarified by
filtration through 0.22 micron cellulose acetate syringe filter and
ultracentrifuged. Viruses were purified with the OptiPrep velocity
gradient method (Axis-Shield PoC, Oslo, Norway). This method-
ology precludes having secreted products such as cytokines in the
viral preparations. The 50% tissue culture infectious dose (TCID
50) of HIV-1 stock was calculated by using the nonparametric
methods of Spearman-Ka ¨rber [58]. TZM-BL cell line was used to
standardize every viral stock used in this study.
Treatment and infection of macrophages
After allowing monocytes to differentiate for 5 days, purified
primary macrophages were treated 18 hours with 1000 IU/ml of
IFNa2 (PBL Biomedical Laboratories, Piscataway, NJ), which
represents the lowest concentration achieving maximum inhibition
of HIV-1 NL4-3BaLenv strain replication in these cells [3]. Pre-
treated macrophages (18 hours) were infected with the NL4-
3BaLenv strain of HIV-1 at a MOI of 0.002 (physiological dose).
Uninfected and untreated cells were used as controls. Aliquots of
cells (3610
6 cells) were taken at 2, 4, 8, and 24 hours after
infection, lysed in 1 ml of TRIzol (Invitrogen Canada, Burlington,
ON) and stored at 280uC.
RNA isolation, labeling, and array hybridization
Total RNA from the same donor was isolated for each condition
and time point using the TRIzol method according to the
manufacturer’s instructions (Invitrogen Canada, Burlington, ON)
and then digested with deoxyribonuclease to remove any
contaminating genomic DNA (Turbo DNA-free, Ambion, Applied
Biosystems Canada, Streetsville, ON). RNA quality and quantity
was assessed using an Agilent Technologies 2100 bioanalyzer and
RNA 6000 Nano LabChip kit (Agilent Technologies Canada,
Mississauga, ON). RNA integrity numbers (RIN), which estimate
the integrity of total RNA samples, ranged from intact (RIN 10) to
degraded (RIN 2). RIN were above eight for all samples in our
experiments. Total RNA (100 ng) was converted to complemen-
tary DNA (cDNA), which was amplified and transcribed to
produce biotinylated cRNA using the Two-Cycle cDNA synthesis
kit (Affymetrix, Santa Clara, CA). Fragmented cRNA (15 mg) were
hybridized to Affymetrix Human Genome U133 Plus 2.0 arrays
(Affymetrix, Santa Clara, CA) for 16 h at 45uC with constant
rotation at 60 rpm. The arrays were washed and stained with
streptavidin-phycoerythrin (Molecular Probes, Eugene, OR) and
biotinylated goat anti-streptavidin (Vector Laboratories, Burlin-
game, CA) using the Affymetrix Fluidics Station 450 (protocol
EukGE-WS2v5_450), then read using the Affymetrix GeneChip
Scanner 3000.
Oligonucleotide array gene expression analysis
GeneChip Robust Multi-array Average (GCRMA) was the
procedure used to normalize the data obtained from the
oligonucleotide array analysis [59]. Identification of the most
differentially expressed genes between IFNa2 pre-treated macro-
phages infected or not with HIV-1 was done using the short time
series analysis framework of Shah and Corbeil [33]. This
framework generalizes the Hilbert-Schmidt Independence Crite-
rion (HSIC) based framework of Song and collaborators [60] to
the short time-series setting by utilizing tensor analysis techniques
resulting in a generic analysis tool that allows both identification of
most differentially expressed genes and patterns of interest in gene
behavior (such as upregulation by IFNa2 with subsequent
suppression by HIV-1). We incorporated a linear kernel in the
framework, and obtain a ranking criterion, which is analogous to
the classical mean-difference based criterion for static gene
expression data [33,61]. The criterion is based on averaging the
differences between consecutive measurements scaled by their
respective means, over all the time points. The framework also
allows identification of highly non-monotonic variations in gene
behavior. The most differentially expressed genes were then
extracted using an empirically determined threshold over the
ranking scores. These genes were then analyzed with respect to
their functionalities and ontological classification using the
DAVID analysis software to determine significant functionalities
associated with HIV-1 infection after IFNa2 treatment of the cells
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between IFNa2 macrophages that were either infected with HIV-1
or non-infected were analyzed to determine which genes had an
association with the keyword interferon using Chilibot software
[62].
qRT-PCR examination of gene expression
cDNA from independent donor cultures was generated from
200 ng of total RNA using a random primer hexamer following
the instructions for Superscript II (Invitrogen Canada, Burling-
ton, ON). Primers were designed using Primer Express 2.0
(Applied Biosystems Canada, Streetsville, ON) and their sequenc-
es are presented in Table 4. Amplicons were detected in most
cases using the Amplifluor UniPrimer amplification and detection
system (Chemicon International, Temecula, CA) except for TAT
spliced message, a marker of HIV replication, which was detected
using the TaqMan system (Applied Biosystems Canada, Streets-
ville, ON), which allows for greater sensitivity and can detect
infection as early as 2 hours post-inoculation. Forward primers
used in the Amplifluor UniPrimer system contained an additional
59 Z sequence (ACTGAACCTGACCGTACA) that is not
included in Table 4. Equal amounts of cDNA (20 ng) were run
in triplicate and amplified using the Amplifluor Uniprimer in a
15 ml reaction containing 7.5 ml of 2X Universal PCR Master
Mix (Applied Biosystems Canada, Streetsville, ON), 10 nM of Z-
tailed forward primer, 100 nM of reverse primer, 100 nM of
Amplifluor Uniprimer fluorescein probe (Chemicon Internation-
al, Temecula, CA) and 5 ml of DNA target [63]. Moreover, no-
template controls were used. The mixture was incubated at 50uC
for 2 min, at 95uC for 4 min, then cycled at 95uCf o r1 5s e ca n d
at 55uC for 40 sec, 55 times using the Applied Biosystems
7900HT Sequence Detection System. The amplifications using
the Taqman system were run in a 15 ml reaction containing
7.5 ml of 2X Universal PCR Master Mix, 200 nM of forward
primer, 200 nM of reverse primer, 250 nM of Taqman probe
and 5 ml of DNA target. The mixture was incubated at 50uCf o r
2 min, at 95uC for 10 min, then cycled 40 times at 95uCf o r
15 sec and at 60uC for 1 min. Amplification efficiencies were
validated and normalized to ribosomal 18 S and quantity of
target gene (arbitrary units) was calculated according to a
standard curve. The standard curve consists of different dilution
of a RNA sample that generates data points in the linear portion
of the PCR amplification.
Enzyme-linked immunosorbent assay (ELISA)
Macrophages were infected with HIV-1 at a MOI of 0.002 for
2 hours at 37uC. Next, the virus-cell mixture was washed with PBS
to remove unbound virus. The p24 content was determined using
a sensitive in-house double-antibody sandwich ELISA specific for
the viral p24 protein. In this test, the 183-H12-5C and 31-90-25
antibodies are used in combination to quantify p24 levels. Virus
production was estimated by measuring p24 levels in cell free
culture supernatants.
Knockdown assays
Macrophages from healthy donors were transfected with
pre-designed siRNA SMARTpool for TRAF6 (M-004712-00;
Dharmacon, Lafayette, CO), VISA (L-024237-00; Dharmacon,
Lafayette, CO) or IRF7 (L-011810-00; Dharmacon, Lafayette,
CO) with the Oligofectamine Transfection Reagent according
to the manufacturer’s instructions (Invitrogen Canada, Burling-
ton, ON). SMARTpool technology combines four siRNAs that
target different mRNA regions. Silencer Negative control
siRNAs (AM4635; Ambion, Applied Biosystems Canada,
Streetsville, ON), used as control do not target any human
gene product. The best gene expression inhibition levels of 65%,
61% and 55% were obtained for TRAF6, VISA and IRF7,
respectively, 48 hours post-transfection (see Figure S2 for
TRAF6 results). The transfected macrophages were then
infected with the NL4-3BaLenv strain of HIV-1 at an MOI of
0.002 for 24 hours. In the case of IFNa2 pre-treatment,
30 hours post-transfection the macrophages were treated for
18 hours before the infection.
Protein assays
Immunoblot assays were performed on total cell lysates of
independent donors. Proteins were isolated for each condition
using total extract buffer (Tris-base pH 6.8, SDS 20%, mercap-
toethanol and glycerol). Cell extracts (30 mg per lane) were
resolved by SDS-PAGE on 4–20% gels (BIO-RAD Laboratories
Canada Ltd, Mississauga, ON) and transferred on PVDF
membranes. The indicated antibodies against IRF7 (H-246; Santa
Cruz Biotechnology, Santa Cruz, CA), IRF3 (SL-12.1; BD-
Pharmingen, Oakville, ON), TRAF6 (H-274; Santa Cruz
Biotechnology, Santa Cruz, CA) and b-actin (A-13; SIGMA,
Saint-Louis, MO) were visualized by alkaline phosphatase-based
enhanced chemiluminescence. The densitometry of the bands was
compared after normalization with b-actin.
Overexpression assays
Macrophages (15610
6 cells) from healthy donors were trans-
fected with 9 mg of pcDNA3-IRF7-myc (Kindly provided by J.
Hiscott, McGill University, Montre ´al, QC) or pcDNA3 (empty
vector control) with the Lipofectamine Transfection Reagent
according to the manufacturer’s instructions (Invitrogen Canada,
Burlington, ON). We obtained the best gene overexpression after
24 hours of transfection, after which, the transfected macrophages
were infected with the NL4-3BaLenv strain of HIV-1 at a MOI of
0.002 for 24 hours.
Microarray data accession number
Microarray results have been deposited in Gene Expression
Omnibus database under accession number GSE30536.
Table 4. Sequence of Oligonucleotide Primers used in Real-
Time qRT-PCR Gene Expression Analysis.
Primer
a Nucleotide Sequence
TRAF6-F AAGGGATGCAGGTCACAAATGT
TRAF6-R TTTTCCAGCAGTATTTCATTGTCAA
VISA-F ACTTCATTGCGGCACTGAGG
VISA-R CTTCGTCCGCGAGATCAACT
IRF7-F CGACATCGAGTGCTTCCTTATG
IRF7-R ACTGGGTTCTAGGCGGGC
IRF3-F TCTGATACCCAGGAAGACATTCTG
IRF3-R CAACACCATGTTACCCAGTAACTCAT
TAT Spliced-F
b CCTAAAACTGCTTGTACCAATTGC
TAT Spliced-R
b GGAGGTGGGTTGCTTTGATAGAGA
TAT Spliced-probe
b AAAGCCTTAGGCATCTC
aF (forward) primer sequence is in 59-39 orientation, R (reverse) primer sequence
is reverse complemented.
bTAT Spliced was detected using Taqman.
doi:10.1371/journal.pone.0028125.t004
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Analysis was performed by paired t-test to compare two
population means in the case of two samples that are correlated
(same donor) or one sample t-test to compare the sample mean to
the population mean (control). P values of less than 0.05 were
considered to be statistically significant.
Ethics statement
Comite ´ d’e ´thique de la recherche du CHUQ approved the
study and written informed consent was provided by study
participants.
Supporting Information
Figure S1 Transactivation of the HIV-1 LTR by IRF1,
IRF3 and IRF7. Expression vector for IRFs and
pBlue_59_LTR_LUC were co-transfected in primary macrophag-
es. Luciferase activity (RLU) was measured at 24 h post-
transfection. Results are the mean of two separate experiments.
(TIF)
Figure S2 Western blot for TRAF6 24 hours post-
infection of macrophages knockdown with 50, 100, 200
and 500 nM of TRAF6 siRNAs. b-actin was used as a
normalizer for input. 200 nM of siRNA were used since a better
percentage of inhibition in TRAF6 knockdown experiments were
obtained at this concentration with respect to the protein level
(67%).
(TIF)
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